🇺🇸 FDA

Drug profile · INN

ranolazine

RANEXA (PREVIOUSLY LATIXA)

FDA: approved EMA: approved C01EB18
US status
approved
Patents linked
0
News articles
0

Quick answer

ranolazine (RANEXA (PREVIOUSLY LATIXA)) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN ranolazine
Brand RANEXA (PREVIOUSLY LATIXA)
Route ORAL
Formulation GRANULE, EXTENDED RELEASE
ATC code C01EB18
Originator Amneal Pharma Europe Ltd

Frequently asked questions

What is ranolazine?

ranolazine (RANEXA (PREVIOUSLY LATIXA)) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for ranolazine?

RANEXA (PREVIOUSLY LATIXA) is a marketed brand name for ranolazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ranolazine?

ranolazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.